Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas

Fertility and Sterility

Volumn 91, Issue 6, 2009, Pages 2664-2675

  Peng, Lan ^a   Wen, Yong ^a   Han, Yulong ^a   Wei, Anran ^a   Shi, Guizhi ^a   Mizuguchi, Masashi ^b   Lee, Peng ^a   Hernando, Eva ^a   Mittal, Khush ^a   Wei, Jian Jun ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

IGF pathway; IGF 1; IGF 2; leiomyomas; promoter; tissue microarray

Indexed keywords

DNA; MESSENGER RNA; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; TUBERIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FROZEN SECTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SIGNAL TRANSDUCTION; SYMPTOM; TISSUE MICROARRAY; UPREGULATION; UTERUS MYOMA; WESTERN BLOTTING;

COHORT STUDIES; DNA PRIMERS; EXONS; FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BIOSYNTHESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOMATOMEDINS; TRANSCRIPTION, GENETIC; UTERINE NEOPLASMS;

EID: 67349265981     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.10.083     Document Type: Article

References (46)

1. Day Baird D., Dunson D.B., Hill M.C., Cousins D., and Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188 (2003) 100-107
2. Varol N., Healey M., Tang P., Sheehan P., Maher P., and Hill D. Ten-year review of hysterectomy morbidity and mortality: can we change direction?. Aust N Z J Obstet Gynaecol 41 (2001) 295-302
3. Davis B. Uterine leiomyoma longitudinal interventions studies: the Fibroid Growth Study. Advances in uterine leiomyoma research: 2nd NIH International Congress (2005), National Institutes of Health, Bethesda, MD
4. DeWaay D.J., Syrop C.H., Nygaard I.E., Davis W.A., and Van Voorhis B.J. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 100 (2002) 3-7
5. Arslan A.A., Gold L.I., Mittal K., Suen T.C., Belitskaya-Levy I., Tang M.S., et al. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 20 (2005) 852-863
6. Dixon D., He H., and Haseman J.K. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 108 Suppl 5 (2000) 795-802
7. Burroughs K.D., Howe S.R., Okubo Y., Fuchs-Young R., LeRoith D., and Walker C.L. Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol 172 (2002) 83-93
8. Giudice L.C., Irwin J.C., Dsupin B.A., Pannier E.M., Jin I.H., Vu T.H., et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 8 (1993) 1796-1806
9. Gloudemans T., Prinsen I., Van Unnik J.A., Lips C.J., Den Otter W., and Sussenbach J.S. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res 50 (1990) 6689-6695
10. Englund K., Lindblom B., Carlstrom K., Gustavsson I., Sjoblom P., and Blanck A. Gene expression and tissue concentrations of IGF-I in human myometrium and fibroids under different hormonal conditions. Mol Hum Reprod 6 (2000) 915-920
11. Martel K.M., Ko A.C., Christman G.M., and Stribley J.M. Apoptosis in human uterine leiomyomas. Semin Reprod Med 22 (2004) 91-103
12. Gao Z., Matsuo H., Wang Y., Nakago S., and Maruo T. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 86 (2001) 5593-5599
13. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4 (2004) 505-518
14. Boehm K.D., Daimon M., Gorodeski I.G., Sheean L.A., Utian W.H., and Ilan J. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 27 (1990) 93-101
15. Skubitz K.M., and Skubitz A.P. Differential gene expression in uterine leiomyoma. J Lab Clin Med 141 (2003) 297-308
16. Ahn W.S., Kim K.W., Bae S.M., Yoon J.H., Lee J.M., Namkoong S.E., et al. Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int J Exp Pathol 84 (2003) 267-279
17. Wang H., Mahadevappa M., Yamamoto K., Wen Y., Chen B., Warrington J.A., et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 80 (2003) 266-276
18. Catherino W.H., Prupas C., Tsibris J.C., Leppert P.C., Payson M., Nieman L.K., et al. Strategy for elucidating differentially expressed genes in leiomyomata identified by microarray technology. Fertil Steril 80 (2003) 282-290
19. Tsibris J.C., Segars J., Coppola D., Mane S., Wilbanks G.D., O'Brien W.F., et al. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 78 (2002) 114-121
20. Weston G., Trajstman A.C., Gargett C.E., Manuelpillai U., Vollenhoven B.J., and Rogers P.A. Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium. Mol Hum Reprod 9 (2003) 541-549
21. Hoffman P.J., Milliken D.B., Gregg L.C., Davis R.R., and Gregg J.P. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 82 (2004) 639-649
22. Vu T.H., Yballe C., Boonyanit S., and Hoffman A.R. Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J Clin Endocrinol Metab 80 (1995) 1670-1676
23. Hashimoto K., Azuma C., Kamiura S., Koyama M., Nobunaga T., Tokugawa Y., et al. Maintenance of imprinting of the insulin-like growth factor II gene (IGF2) and the small nuclear ribonucleoprotein polypeptide N gene (SNRPN) in the human uterus and leiomyoma. Gynecol Obstet Invest 41 (1996) 50-54
24. Rainho C.A., Pontes A., and Rogatto S.R. Expression and imprinting of insulin-like growth factor II (IGF2) and H19 genes in uterine leiomyomas. Gynecol Oncol 74 (1999) 375-380
25. Kovacs K.A., Lengyel F., Kornyei J.L., Vertes Z., Szabo I., Sumegi B., et al. Differential expression of Akt/protein kinase B, Bcl-2 and Bax proteins in human leiomyoma and myometrium. J Steroid Biochem Mol Biol 87 (2003) 233-240
26. Martin Chaves E.B., Brum I.S., Stoll J., Capp E., and Corleta H.E. Insulin-like growth factor 1 receptor mRNA expression and autophosphorylation in human myometrium and leiomyoma. Gynecol Obstet Invest 57 (2004) 210-213
27. De Leo V., la Marca A., Morgante G., Severi F.M., and Petraglia F. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Fertil Steril 75 (2001) 632-633
28. Wei J., Chiriboga L., Mizuguchi M., Yee H., and Mittal K. Expression profile of tuberin and some potential tumorigenic factors in 60 patients with uterine leiomyomata. Mod Pathol 18 (2005) 179-188
29. Wei J.J., Chiriboga L., Arslan A.A., Melamed J., Yee H., and Mittal K. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod 21 (2006) 57-67
30. Mineo R., Fichera E., Liang S.J., and Fujita-Yamaguchi Y. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. Biochem Biophys Res Commun 268 (2000) 886-892
31. Klotz D.M., Hewitt S.C., Ciana P., Raviscioni M., Lindzey J.K., Foley J., et al. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem 277 (2002) 8531-8537
32. Vu T.H., and Hoffman A.R. Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature 371 (1994) 714-717
33. Manning B.D., Logsdon M.N., Lipovsky A.I., Abbott D., Kwiatkowski D.J., and Cantley L.C. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19 (2005) 1773-1778
34. Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4 (2002) 658-665
35. Plas D.R., and Thompson C.B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278 (2003) 12361-12366
36. Hoppener J.W., Mosselman S., Roholl P.J., Lambrechts C., Slebos R.J., de Pagter-Holthuizen P., et al. Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours. EMBO J 7 (1988) 1379-1385
37. Wang T., Zhang X., Obijuru L., Laser J., Aris V., Lee P., et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46 (2007) 336-347
38. Yee D., and Lee A.V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 5 (2000) 107-115
39. Zollers Jr. W.G., Babischkin J.S., Pepe G.J., and Albrecht E.D. Developmental regulation of placental insulin-like growth factor (IGF)-II and IGF-binding protein-1 and -2 messenger RNA expression during primate pregnancy. Biol Reprod 65 (2001) 1208-1214
40. Szabo P.E., Pfeifer G.P., and Mann J.R. Parent-of-origin-specific binding of nuclear hormone receptor complexes in the H19-Igf2 imprinting control region. Mol Cell Biol 24 (2004) 4858-4868
41. Hartmann W., Waha A., Koch A., Albrecht S., Gray S.G., Ekstrom T.J., et al. Promoter-specific transcription of the IGF2 gene: a novel rapid, non-radioactive and highly sensitive protocol for mRNA analysis. Virchows Arch 439 (2001) 803-807
42. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
43. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11 (2003) 1457-1466
44. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10 (2002) 151-162
45. Hunter D.S., Klotzbucher M., Kugoh H., Cai S.L., Mullen J.P., Manfioletti G., et al. Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function. Cancer Res 62 (2002) 3766-3772
46. Ma L., Teruya-Feldstein J., Bonner P., Bernardi R., Franz D.N., Witte D., et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 67 (2007) 7106-7112